Alkem Laboratories Limited Total Assets
Alkem Laboratories Limited total assets. Based on the latest financial reports, Alkem Laboratories Limited (ALKEM) holds total assets worth Rs202.87 Billion INR (≈ $2.19 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALKEM market cap for the company's overall valuation and market capitalisation.
Total Assets of Alkem Laboratories Limited (2010–2025)
Total assets of Alkem Laboratories Limited from 2010 to 2025. This chart illustrates how Alkem Laboratories Limited's total assets have evolved over time, based on quarterly financial data. See today's stock price for Alkem Laboratories Limited for real-time trading data and today's change.
Alkem Laboratories Limited - Asset Composition Analysis
Alkem Laboratories Limited Total Assets Breakdown (March 2025)
Alkem Laboratories Limited total assets breakdown as of March 2025. Alkem Laboratories Limited's total assets of Rs202.87 Billion consist of 61.9% current assets and 38.1% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs1.07 Billion | 1.7% |
| Accounts Receivable | Rs24.75 Billion | 14.0% |
| Inventory | Rs29.22 Billion | 16.5% |
| Property, Plant & Equipment | Rs28.63 Billion | 16.2% |
| Intangible Assets | Rs1.15 Billion | 0.7% |
| Goodwill | Rs4.23 Billion | 2.4% |
Asset Composition Trend (2010–2025)
This chart illustrates how Alkem Laboratories Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Alkem Laboratories Limited to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alkem Laboratories Limited's current assets represent 61.9% of total assets in 2025, a decrease from 73.1% in 2010.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2025, down from 42.4% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is inventory at 16.5% of total assets.
Alkem Laboratories Limited Competitors by Total Assets
Key competitors of Alkem Laboratories Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs96.12 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SHE:002793
|
China | CN¥3.61 Billion |
Alkem Laboratories Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.49 | 2.66 | 1.98 |
| Quick Ratio | 1.87 | 1.96 | 1.32 |
| Cash Ratio | 0.32 | 0.47 | 0.00 |
| Working Capital | Rs72.48 Billion | Rs69.32 Billion | Rs29.51 Billion |
Alkem Laboratories Limited - Advanced Valuation Insights
This section examines the relationship between Alkem Laboratories Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.00 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 13.6% |
| Total Assets | Rs176.91 Billion |
| Market Capitalization | $6.85 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Alkem Laboratories Limited's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Alkem Laboratories Limited's assets grew by 13.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alkem Laboratories Limited (2010–2025)
The table below shows the annual total assets of Alkem Laboratories Limited from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs176.91 Billion ≈ $1.91 Billion |
+13.59% |
| 2024-03-31 | Rs155.75 Billion ≈ $1.68 Billion |
+13.22% |
| 2023-03-31 | Rs137.57 Billion ≈ $1.49 Billion |
-2.22% |
| 2022-03-31 | Rs140.69 Billion ≈ $1.52 Billion |
+22.14% |
| 2021-03-31 | Rs115.19 Billion ≈ $1.25 Billion |
+15.82% |
| 2020-03-31 | Rs99.46 Billion ≈ $1.08 Billion |
+21.17% |
| 2019-03-31 | Rs82.08 Billion ≈ $887.68 Million |
+7.08% |
| 2018-03-31 | Rs76.66 Billion ≈ $829.01 Million |
+16.71% |
| 2017-03-31 | Rs65.68 Billion ≈ $710.31 Million |
+18.67% |
| 2016-03-31 | Rs55.35 Billion ≈ $598.55 Million |
+4.51% |
| 2015-03-31 | Rs52.96 Billion ≈ $572.72 Million |
+21.81% |
| 2014-03-31 | Rs43.48 Billion ≈ $470.19 Million |
+7.40% |
| 2013-03-31 | Rs40.48 Billion ≈ $437.80 Million |
+27.21% |
| 2012-03-31 | Rs31.82 Billion ≈ $344.16 Million |
+22.90% |
| 2011-03-31 | Rs25.89 Billion ≈ $280.03 Million |
+66.05% |
| 2010-03-31 | Rs15.59 Billion ≈ $168.64 Million |
-- |
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective… Read more